Vilon (20mg)

Vilon (20mg) is a lyophilized research peptide synthesized, purified, and lyophilized in the USA. Each production batch is purified by repeated rounds of reverse-phase HPLC and identity-confirmed by mass spectrometry.

Current investigation of Vilon (20mg) focuses on its stability under storage conditions and its signaling activity in vitro.

Vilon (20mg) is investigated in longevity-oriented research for its influence on cellular energy systems and stress resilience.

Studies of Vilon (20mg) often measure mitochondrial or redox endpoints in cultured models to characterize its research potential.

Each vial contains lyophilized peptide at the labeled quantity, and wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only —not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with Vilon (20mg). Summaries are provided for orientation only and reflect the cited sources.

Peptidegic stimulation of differentiation of pineal immune cells^[1] —This study investigated the ability of the dipeptide vilon (Lys-Glu) to stimulate differentiation of immune cell precursors in the pineal gland. The authors report that vilon promotes their differentiation into T-helper, cytotoxic T, and B cells. The findings suggest the peptide may help compensate for age-related thymic atrophy. (Bulletin of Experimental Biology and Medicine 2011)

Effects of short peptides on lymphocyte chromatin in senile subjects^[2] —This study evaluated the effects of short peptides, including vilon, on the chromatin state of lymphocytes from elderly individuals. The authors report immunomodulatory changes consistent with improved cellular function. These results support the proposed role of vilon in immune ageing research. (Bulletin of Experimental Biology and Medicine 2004)

Peptides and Ageing^[3] —This review describes tissue-specific peptide bioregulators and their roles in ageing, including the thymic dipeptide vilon (Lys-Glu). The author presents vilon as a peptide with immunoprotective and geroprotective activity. The review situates such peptides within a broader framework of peptide regulation of ageing. (Neuro Endocrinology Letters 2002)

References

1. Linkova NS, Khavinson VKh, Chalisova NI, Katanugina AS, Koncevaya EA. "Peptidegic stimulation of differentiation of pineal immune cells." Bulletin of Experimental Biology and Medicine. 2011. pubmed.ncbi.nlm.nih.gov/22803057/
2. Khavinson VKh, Lezhava TA, Malinin VV. "Effects of short peptides on lymphocyte chromatin in senile subjects." Bulletin of Experimental Biology and Medicine. 2004. pubmed.ncbi.nlm.nih.gov/15085253/
3. Khavinson VKh. "Peptides and Ageing." Neuro Endocrinology Letters. 2002. pubmed.ncbi.nlm.nih.gov/12374906/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.